Improving survival for patients with high-risk congenital diaphragmatic hernia by using extracorporeal membrane oxygenation

• Published in: Journal of pediatric surgery Vol. 30; no. 10; pp. 1463 - 1467
• Main Authors: vd Staak, F.H.J.M, de Haan, A.F.J, Geven, W.B, Doesburg, W.H, Festen, C
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Elsevier Inc 01.10.1995; Elsevier
• Subjects: Biological and medical sciences; Extracorporeal Membrane Oxygenation; Female; Hernia, Diaphragmatic - mortality; Hernia, Diaphragmatic - surgery; Hernias, Diaphragmatic, Congenital; Humans; Infant, Newborn; Male; Medical sciences; Pneumology; Respiratory system : syndromes and miscellaneous diseases; Risk Factors; Survival Rate; Congenital diaphragmatic hernia; extracorporeal membrane oxygenation; Human; High risk; Congenital; Respiratory disease; Survival; Cardiopulmonary bypass; Hernia; Newborn; Treatment; Respiratory muscle; Malformation; Diaphragm; Resuscitation
• ISSN: 0022-3468; 1531-5037
• DOI: 10.1016/0022-3468(95)90408-5

The benefit of extracorporeal membrane oxygenation (ECMO) in cases of high-risk congenital diaphragmatic hernia (CDH) was studied by comparing pre-ECMO (1987–1990) and post-ECMO (1991–1994) 3-month survival statistics. Fifty-five CDH patients who presented in respiratory distress within 6 hours after birth were referred—18 in the pre-ECMO era and 37 in the ECMO era. During the entire study period (December 1987 through July 1994) the patients were treated by the same protocol of preoperative stabilization and delayed surgery; the only difference was the addition of ECMO beginning in January 1991. The patients were stratified based on the response to conventional treatment: 1, no response (irretrievable); 2, stable; 3, unstable. The 3-month survival rate for the unstable neonates (who could not be stabilized by conventional therapy) improved from 0% (0 of 9) in the pre-ECMO era to 61% (11 of 18) in the ECMO era ( P = .004). This highly significant difference shows that ECMO is a very valuable addition to the management of high-risk CDH patients whose conditions remain unstable despite maximal conventional therapy.